BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1663-1667

  Chen, Yanglin ^a   Zhou, Jing ^a   Xu, Ye ^a   Li, Zhaosheng ^a   Wen, Xianzi ^a   Yao, Lihua ^a   Xie, Yuntao ^a   Deng, Dajun ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; DNA;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COLLOID CARCINOMA; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG CARCINOMA; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE;

EID: 70149093412     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01225.x     Document Type: Article

References (23)

1. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
2. Ralhan R, Kaur J, Kreienberg R, Wiesmüller L. Links between DNA double strand break repair and breast cancer. Accumulating evidence from both familial and nonfamilial cases. Cancer Lett 2007; 248: 1-17.
3. van der Looij M, Cleton-Jansen AM, van Eijk R et al. A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1.Genes Chromosomes Cancer 2000; 27: 295-302.
4. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9: 444-50.
5. Costello JF, Frühwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132-8.
6. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-40.
7. Herman JG, Baylin SB. Mechanisms of disease: gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer.Nat Rev Genet 2002; 3: 415-28.
9. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-9.
10. Jeronimo C, Costa I, Martins MC et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003; 9: 3413-7.
11. Jing F, Zhang J, Tao J et al. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients.Onkologie 2007; 30: 14-9.
12. Xu X, Gammon MD, Zhang Y et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009; 115: 397-404.
13. Xu Y, Yao L, Li H et al. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Breast Cancer Res Treat 2006; 97:49-55.
14. Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA). In:Mills KI, Ramsahoye BH, eds. DNA Methylation Protocols (Methods in Molecular Biology, Vol. 200). Totowa, NJ: Humana Press, 2002; 53-70.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
16. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
17. Gordon S, Kim A, Maureen I. Primary Ovarian Carcinomas Display Multiple Methylator Phenotypes Involving Known Tumor Suppressor Genes. Am J Pathol 2001; 158: 1121-7.
18. Cuiju W, Akiko H, Tsutomu I. Expression of BRCA1 protein in benign,borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 2004; 202: 215-23.
19. Kwong A, Cheung P, Chan S, Lau S. Breast cancer in Chinese women younger than age 40: are they different from their older counterparts? World J Surg 2008; 32: 2554-61.
20. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment,and survival by race and ethnicity. Arch Intern Med 2003; 163: 49-56.
21. Hutter RV. The role of the pathologist in breast cancer management. Cancer 1990; 66(6 Suppl): 1363-72.
22. Saal LH, Gruvberger-Saal SK, Persson C et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2007; 40: 102-7.
23. Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW.An overview of prognostic factors for long-term survivors of breast cancer.Breast Cancer Res Treat 2008; 107: 309-30.